News

ArQule is involved in the research and development of targeted therapeutics for the treatment of cancers and certain rare diseases. The company’s clinical-stage pipeline consists of four drug

According to XBiotech, bermekimab has been designed to neutralise interleukin-1 alpha (IL-1⍺), which is known for promoting disease-causing inflammation in a wide variety of medical conditions. As per

These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from

The Independent Review Committee (IRC)-assessed results were presented at the 2019 American Society of Hematology Annual Meeting and Exhibition in Orlando, US. At a median follow-up of 28.3

Liso-cel is an investigational CD19-directed chimeric antigen receptor (CAR) T-cell therapy with a defined composition of purified CD8+ and CD4+ CAR T cells in relapsed/refractory large B-cell lymphomas.

Founded in 2017, Limelight Bio has developed proprietary technologies, advanced targets and leading drug candidates designed to overcome key limitations of current gene therapy and gene editing approaches.

FKD Therapies Oy (FKD) has led the development and regulatory filing of nadofaragene firadenovec, which has been studied in 33 centers across the U.S. in collaboration with the

Meitheal licenses Enoxaparin Sodium Injection exclusively through its partnership with Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (NKF), its majority shareholder. Enoxaparin had annual sales of approximately $616M in

The company has completed the submission of a new drug application (NDA) to the regulator for fostemsavir. Fostemsavir, an investigational prodrug of temsavir, is a first-in-class HIV-1 attachment